| Tacrolimus - Wikipedia, the free encyclopedia Tacrolimus (also FK-506 or fujimycin, trade names Prograf, Advagraf, Protopic) is an immunosuppressive drug that is mainly used after allogeneic organ transplant to ... Read More |
| tacrolimus (oral) medical facts from Drugs.com Physician reviewed tacrolimus (oral) patient information - includes tacrolimus description, dosage and directions. Read More |
| Tacrolimus Official FDA information, side effects and uses. Accurate, FDA approved Tacrolimus information for healthcare professionals and patients - brought to you by Drugs.com. Read More |
| Tacrolimus: MedlinePlus Drug Information - National Library of ... Tacrolimus should only be given under the supervision of a doctor who is experienced in treating people who have had an organ transplant and in prescribing ... Read More |
| Prograf (Tacrolimus) Drug Information: Description, User Reviews ... Learn about the prescription medication Prograf (Tacrolimus), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Read More |
| Tacrolimus: At a Glance Overview of the test used to measure the blood level of tacrolimus, a drug given to patients who have had an organ transplant Read More |
| Tacrolimus - PubMed Health - National Center for Biotechnology ... Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ ... Read More |
| Tacrolimus. DermNet NZ Tacrolimus. Authoritative facts about the skin from the New Zealand Dermatological Society. Read More |
| Tacrolimus (Prograf) Side Effects, Drug Interactions, Dosage ... Tacrolimus (Prograf) medication for transplant patient side effects, drug interactions, dosage, and drug interaction information. Read More |
| tacrolimus - definition of tacrolimus in the Medical dictionary ... tacrolimus /tac·ro·li·mus/ (tak″ro-li´mus) a macrolide immunosuppressant having actions similar to those of cyclosporine; used to prevent rejection of organ ... Read More |
